Browsing: EGFRMutant

This segment examines single-agent osimertinib as the foundation of first-line EGFR-mutated NSCLC therapy and the benchmark against which combination strategies…

This segment focuses on combining osimertinib with platinum-pemetrexed chemotherapy as a first-line intensification strategy. The faculty walk through the regimen’s…

This segment addresses the chemotherapy-free combination of amivantamab and lazertinib as a first-line option and its distinct safety profile. The…

This segment applies the preceding data to a higher-risk patient: a fit, newly diagnosed individual with a classic sensitizing mutation,…

This closing segment addresses how first-line choice shapes later options and how to approach progression. The faculty stress re-characterizing the…

An updated overall survival (OS) analysis from the global phase 3 HARMONi trial (NCT05899608) showed that ivonescimab plus platinum-doublet chemotherapy…

This segment turns from data to the patient conversation, focusing on the preconceptions people bring to treatment decisions. The faculty…

This opening segment frames how first-line management of EGFR-mutatedadvanced non-small cell lung cancer has shifted from a single-agent standard to…

With the molecular picture established, the discussion turns to how a confirmed EGFR mutation translates into a first-line treatment decision.…

The FLAURA2 phase three trial demonstrated that adding platinum-based chemotherapy to osimertinib significantly improved outcomes over osimertinib monotherapy in first-line…